NCT05945368 2023-07-14
A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
Clinical Trials
9 trialsNCT05429294 2022-06-23
Novel Double Target Therapy Combined With Chemotherapy in First-line Treatment of HER2+ Breast Cancer, MA-BC-II-038
First Affiliated Hospital Xi'an Jiaotong University
Phase 2 Unknown
NCT05334810 2022-04-19
DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Unknown
NCT05154396 2021-12-13
Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer
ChineseAMS
Phase 2 Unknown
NCT03238495 2021-12-07
HERMET
University of Kansas Medical Center
Phase 2 Unknown
NCT03933319 2020-07-08
Phase Ⅱ Study of Pegylated Liposomal Doxorubicin（PLD）Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer
ChineseAMS
Phase 2 Unknown
NCT04034823 2019-07-26
KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Unknown
NCT03919253 2019-04-18
Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study
Hebei Medical University Fourth Hospital
Phase 2 Unknown
NCT03684863 2018-09-26
Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy
Shandong Cancer Hospital and Institute
Phase 2 Unknown